S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   309.08 (-0.41%)
AAPL   158.99 (-0.18%)
MSFT   274.12 (+0.12%)
META   201.51 (-0.32%)
GOOGL   104.13 (-0.75%)
AMZN   101.07 (+0.46%)
TSLA   192.21 (-2.72%)
NVDA   267.25 (+2.01%)
NIO   9.12 (-1.62%)
BABA   83.84 (+0.17%)
AMD   98.52 (+2.70%)
T   18.50 (-0.22%)
F   11.55 (-1.45%)
MU   58.64 (+0.02%)
CGC   1.90 (-3.55%)
GE   90.16 (-2.19%)
DIS   96.87 (+0.34%)
AMC   4.37 (-0.91%)
PFE   40.23 (-1.06%)
PYPL   74.82 (-2.48%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   309.08 (-0.41%)
AAPL   158.99 (-0.18%)
MSFT   274.12 (+0.12%)
META   201.51 (-0.32%)
GOOGL   104.13 (-0.75%)
AMZN   101.07 (+0.46%)
TSLA   192.21 (-2.72%)
NVDA   267.25 (+2.01%)
NIO   9.12 (-1.62%)
BABA   83.84 (+0.17%)
AMD   98.52 (+2.70%)
T   18.50 (-0.22%)
F   11.55 (-1.45%)
MU   58.64 (+0.02%)
CGC   1.90 (-3.55%)
GE   90.16 (-2.19%)
DIS   96.87 (+0.34%)
AMC   4.37 (-0.91%)
PFE   40.23 (-1.06%)
PYPL   74.82 (-2.48%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   309.08 (-0.41%)
AAPL   158.99 (-0.18%)
MSFT   274.12 (+0.12%)
META   201.51 (-0.32%)
GOOGL   104.13 (-0.75%)
AMZN   101.07 (+0.46%)
TSLA   192.21 (-2.72%)
NVDA   267.25 (+2.01%)
NIO   9.12 (-1.62%)
BABA   83.84 (+0.17%)
AMD   98.52 (+2.70%)
T   18.50 (-0.22%)
F   11.55 (-1.45%)
MU   58.64 (+0.02%)
CGC   1.90 (-3.55%)
GE   90.16 (-2.19%)
DIS   96.87 (+0.34%)
AMC   4.37 (-0.91%)
PFE   40.23 (-1.06%)
PYPL   74.82 (-2.48%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   309.08 (-0.41%)
AAPL   158.99 (-0.18%)
MSFT   274.12 (+0.12%)
META   201.51 (-0.32%)
GOOGL   104.13 (-0.75%)
AMZN   101.07 (+0.46%)
TSLA   192.21 (-2.72%)
NVDA   267.25 (+2.01%)
NIO   9.12 (-1.62%)
BABA   83.84 (+0.17%)
AMD   98.52 (+2.70%)
T   18.50 (-0.22%)
F   11.55 (-1.45%)
MU   58.64 (+0.02%)
CGC   1.90 (-3.55%)
GE   90.16 (-2.19%)
DIS   96.87 (+0.34%)
AMC   4.37 (-0.91%)
PFE   40.23 (-1.06%)
PYPL   74.82 (-2.48%)
NFLX   300.91 (-1.60%)
NASDAQ:SAVA

Cassava Sciences - SAVA Stock Forecast, Price & News

$23.71
-2.00 (-7.78%)
(As of 03/22/2023 03:52 PM ET)
Add
Compare
Today's Range
$23.58
$25.73
50-Day Range
$24.70
$36.44
52-Week Range
$13.84
$51.59
Volume
1.46 million shs
Average Volume
1.33 million shs
Market Capitalization
$989.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.33

Cassava Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
129.3% Upside
$54.33 Price Target
Short Interest
Bearish
28.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$302,193 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.76) to ($3.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

616th out of 983 stocks

Pharmaceutical Preparations Industry

295th out of 478 stocks


SAVA stock logo

About Cassava Sciences (NASDAQ:SAVA) Stock

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Stock News Headlines

3 Short-Squeeze Stocks to Keep on Your Radar
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Why Cassava Sciences Stock Is Surging After Hours
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call
3 Big Reasons to Sell Cassava Sciences Stock Right Now
Cassava Sciences' Data Once Again Misunderstood
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?
H.C. Wainwright Sticks to Its Buy Rating for Cassava Sciences (SAVA)
See More Headlines
Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Company Calendar

Last Earnings
11/10/2021
Today
3/22/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAVA
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.33
High Stock Price Forecast
$124.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+111.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-76,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.68 per share

Miscellaneous

Free Float
37,532,000
Market Cap
$1.07 billion
Optionable
Not Optionable
Beta
-0.10

Key Executives

  • Remi Barbier
    Chairman, President & Chief Executive Officer
  • Eric J. Schoen
    Chief Financial Officer
  • James W. Kupiec
    Chief Medical Officer
  • Michael Zamloot
    Senior Vice President-Technical Operations
  • George B. Thornton
    Senior Vice President-Technology













SAVA Stock - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SAVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
View SAVA analyst ratings
or view top-rated stocks.

What is Cassava Sciences' stock price forecast for 2023?

3 analysts have issued 12-month price objectives for Cassava Sciences' shares. Their SAVA share price forecasts range from $11.00 to $124.00. On average, they predict the company's share price to reach $54.33 in the next twelve months. This suggests a possible upside of 112.2% from the stock's current price.
View analysts price targets for SAVA
or view top-rated stocks among Wall Street analysts.

How have SAVA shares performed in 2023?

Cassava Sciences' stock was trading at $29.54 at the beginning of 2023. Since then, SAVA stock has decreased by 13.3% and is now trading at $25.60.
View the best growth stocks for 2023 here
.

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our SAVA earnings forecast
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.09.

When did Cassava Sciences' stock split?

Cassava Sciences shares reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Jefferies Financial Group Inc. (0.00%), Geode Capital Management LLC (1.77%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%), Norges Bank (0.82%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Eric Schoen, James William Kupiec, Remi Barbier, Richard Barry and Sanford Robertson.
View institutional ownership trends
.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $25.60.

How much money does Cassava Sciences make?

Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.07 billion. The company earns $-76,250,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414.

This page (NASDAQ:SAVA) was last updated on 3/22/2023 by MarketBeat.com Staff